Maternal and pregnancy outcomes in women offered daily oral preexposure prophylaxis during pregnancy and postpartum
Rattachement africain : us, Zimbabwe, Afrique du Sud, Ouganda, Malawi. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To compare maternal safety and pregnancy outcomes among women who did and did not use daily oral emtricitabine-tenofovir disoproxil fumarate (FTC/TDF) for preexposure prophylaxis (PrEP) during pregnancy and postpartum. DESIGN: Parallel cohort design, with follow-up from pregnancy to 6 months postpartum. SETTING: Seven research clinics in Malawi, South Africa, Uganda, and Zimbabwe. PARTICIPANTS: Three hundred fifty pregnant women aged 16-24 years at 32 weeks or less gestation, meeting local criteria for PrEP. At entry, PrEP initiators and decliners were enrolled 2 : 1. Participants could start or stop PrEP at any time. MAIN OUTCOME MEASURES: Maternal adverse events were defined as grade ≥3 signs, symptoms, and diagnoses, and grade ≥2 chemistry abnormalities according to Division of AIDS toxicity tables. Adverse pregnancy outcomes included fetal loss, preterm birth, and small-for-gestational-age. RESULTS: From March to December 2022, 350 eligible participants enrolled: 229 initiating and 121 declining PrEP at entry. Median duration of PrEP use was 34 weeks (interquartile range [IQR]: 16-40). Sixty maternal adverse events were reported over 230.3 person-years (incidence rate: 25.6, 95% confidence interval [95% CI]: 20.0-32.8). Although those on PrEP had higher rates of adverse events, this was not statistically significant (adjusted incidence rate ratio: 1.84, 95% CI: 0.53-6.30). Most frequent grade ≥3 adverse events were complications of pregnancy or delivery. Five (8%) were considered related to PrEP use. Among those with delivery information, 79 (24%) participants reported adverse pregnancy outcomes, with no differences between PrEP groups. No participants acquired HIV infections during follow-up. CONCLUSION: Daily oral FTC-TDF remains a well tolerated and essential component of HIV prevention in pregnancy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Maternal and pregnancy outcomes in women offered daily oral preexposure prophylaxis during pregnancy and postpartum
- Date Crossref
- 28/07/2026
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of North Carolina at Chapel Hill pays non établi dans la noticeUniversité ou école supérieure
-
Harvard University pays non établi dans la noticeUniversité ou école supérieure
-
Family Health International 360 pays non établi dans la noticeOrganisation à but non lucratif
-
University of Michigan pays non établi dans la noticeUniversité ou école supérieure
-
University of Zimbabwe Harare, Zimbabwe (code pays fourni par la source)Université ou école supérieure
-
University of the Witwatersrand University of the Witwatersrand, Afrique du Sud (code pays fourni par la source)Université ou école supérieure
-
MUJHU Research Collaboration Ouganda (code pays fourni par la source)Structure de recherche
-
University of Malawi Malawi (code pays fourni par la source)Université ou école supérieure
-
Baylor College of Medicine Children’s Foundation Kampala, Ouganda (code pays fourni par la source)Organisation à but non lucratif
-
Frontier Science & Technology Research Foundation pays non établi dans la noticeOrganisation à but non lucratif
-
National Institute of Allergy and Infectious Diseases Kelly Government Solutions pays non établi dans la noticeStructure de recherche
-
Kelly Services (United States) pays non établi dans la noticeEntreprise
University of North Carolina at Chapel Hill, Harvard University et Family Health International 360, avec 9 autres affiliations. Pays d’affiliation : Zimbabwe, Afrique du Sud, Ouganda, Malawi.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.